EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BioPharm America 2014 EBD Group MassBio
Share/Follow Us
Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BioPharm America™ 2015 Program Overview

www.ebdgroup.com/bpa/program
Monday, September 14, 2015
5:30–8:00 pm
Welcome Reception

BioPharm America™ 2015 Welcome Reception
All BioPharm America attendees are cordially invited to join us for a welcome reception.

Boston Marriott Copley Place
Level 3, Atrium Lobby
110 Huntington Avenue
Boston, MA 02116 (map)

You will be able to pick up your name badge at the welcome reception.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Tuesday, September 15, 2015
7:30 am
Level 3, Atrium Lobby
7:30 am
Level 4, Grand Ballroom
Exhibition opens and Continental Breakfast
8:30–10:40 am
Pharma and Large Biotech Presentations
Introduction and Moderation by IMS Health Capital, Inc.


Share this:Email this pageShare this on LinkedInShare this on Twitter
Johnson & Johnson Innovation


Share this:Email this pageShare this on LinkedInShare this on Twitter
Bayer


Share this:Email this pageShare this on LinkedInShare this on Twitter
Baxalta


Share this:Email this pageShare this on LinkedInShare this on Twitter
AstraZeneca


Share this:Email this pageShare this on LinkedInShare this on Twitter
Novo Nordisk


Share this:Email this pageShare this on LinkedInShare this on Twitter
Biogen


Share this:Email this pageShare this on LinkedInShare this on Twitter
9:00–10:30 am
Parallel Workshops
The perfect pitch: Do you have what it takes to win over investors?

What you have to say in 30 seconds could mean the difference between a meeting with an investor and a door closed in your face. Win a one-to-one meeting with a leading life science private equity investor.

Members of the audience will have 30 seconds to give their elevator pitch to a star-studded panel of seasoned industry investors. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First- and second-place winners will receive a full 30-minute private follow-up meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. All are welcome: entrepreneurs, service providers, job seekers, executives and more.

Audience preparation notes:
Participants will be judged on the quality and effectiveness of the overall 30-second pitch. Remember, the primary goal of an elevator pitch is to spark interest for a follow-up meeting. Pre-workshop coaching is available from the moderator (contact: doug@macbiocom.com). Practice, practice, practice!

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Judges:
  • Richard Anders – Founder, Executive Director, Mass Medical Angels
  • Bernard Davitian – VP and Managing Director, Sanofi-Genzyme BioVentures
  • Peter Kolchinsky – Managing Director and Portfolio Manager, RA Capital
  • Sara M. Nayeem – Principal, New Enterprise Associates
  • Marta New – Principal, Baxalta Ventures
  • Dennis J. Purcell – Founder and Senior Advisor, Aisling Capital
  • Phillip Samayoa – Associate Director, MRL Ventures, Merck
  • Geoffrey von Maltzahn – VentureLabs Partner, Flagship Ventures
Share this:Email this pageShare this on LinkedInShare this on Twitter
Big data: Going from buzzword to business

From genomics to drug discovery to compliance, the amount of data the biopharma industry has the ability collect and analyze is staggering. But, there are many questions to be addressed: How can we effectively mine the data to make impactful decisions in R&D? What information is being assessed by payers? Why are certain areas of biotech getting funded where others are not? This panel will address these questions and discuss how big data is being used to help companies more efficiently design clinical studies, enroll targeted patients, and ultimately help drive strategic business decisions.

Moderator:
Chirag Patel – Assistant Professor, Biomedical Informatics, Harvard Medical School

Panelists:
  • Timothy Danford – Field Engineer, Tamr Inc.
  • Keith Elliston – President and CEO, tranSMART Foundation
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45 am–12:15 pm
Level 4, Salon G
Welcome and Opening Plenary Discussion
Welcome Remarks

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Robert Coughlin – President and CEO, MassBio
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opening Plenary Discussion
Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters

There is an increasing number of industry heavy hitters who have successfully led and exited large corporations and are now investing their experience, clout and in some cases, personal finances to reseed the life science ecosystem by leading the charge at small companies. Join us as they provide their perspectives from both sides of the fence, share the "war stories" that got them to where they are, and discuss how their experiences are helping them drive innovative small companies to successfully attack difficult targets at the front lines.

Moderator:
Francois Maisonrouge – Senior Managing Director, Evercore Partners

Panelists:
  • Deborah Dunsire – President and CEO, FORUM Pharmaceuticals
  • Jeffrey B. Kindler – CEO, Centrexion Corp.
  • Jeremy Levin – Chairman and CEO, Ovid Therapeutics Inc.
  • Christopher A. Viehbacher – Managing Partner, Gurnet Point Capital
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Francois Maisonrouge Francois Maisonrouge
Senior Managing Director
Evercore Partners

Speakers:
Deborah Dunsire Jeffrey B. Kindler Jeremy Levin Christopher A. Viehbacher
Deborah Dunsire
President and CEO
FORUM Pharmaceuticals
Jeffrey B. Kindler
CEO
Centrexion Corp.
Jeremy Levin
Chairman and CEO
Ovid Therapeutics Inc.
Christopher A. Viehbacher
Managing Partner
Gurnet Point Capital
12:15–1:30 pm
Level 4, Exhibit Hall
Luncheon
1:30–2:30 pm
Company Presentations: Deutsche Börse Venture Network

1:30 pm Protagen
1:45 pm AYOXXA Biosystems
2:00 pm invendo medical
2:15 pm Curetis

Share this:Email this pageShare this on LinkedInShare this on Twitter
Level 4, Exhibit Hall
1:00–6:00 pm
One-to-one Meetings ►
1:30–2:30 pm
Executive Discussion
Rare diseases: The new norm?

With over 7,000 rare diseases and treatments for only 5% of them, the need for cures is obvious. With that need comes great opportunities—and risks—for drug developers. Though the therapeutic promises for the treatments of rare diseases are greater now than ever before, significant hurdles are in the way of getting patients access to innovative therapies. Heads of leading R&D companies and patient organizations will share their insights on the evolving landscape and discuss the importance of patient engagement and cross-sector collaborations in addressing the opportunities and challenges in financing, clinical trials, pricing, and patient access.

Moderator:
Jeremy Springhorn – Partner, Corporate Development, Flagship Ventures

Panelists:
  • Ilan Ganot – Founder and CEO, Solid Biosciences
  • John Orloff – Executive VP, Global Head of R&D, Chief Scientific Officer, Baxalta
  • Henri Termeer – Former CEO, President and Chairman, Genzyme Corporation
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Jeremy Springhorn Jeremy Springhorn
Partner
Corporate Development
Flagship Ventures

Panelists:
Ilan Ganot John Orloff Henri Termeer
Ilan Ganot
Founder and CEO
Solid Biosciences
John Orloff
Executive VP
Global Head of R&D
Chief Scientific Officer
Baxalta
Henri Termeer
Former CEO
President and Chairman
Genzyme Corporation
2:45–6:15 pm
Parallel Panel Discussions
Dealmaking and Strategy
Externalizing R&D, building efficient pharma

While attempting to maintain a continuous number of potential products, big pharma has had to adjust their acquisition and investment strategy due to declining R&D productivity in recent years. This has resulted in a significant shift from internal to external R&D, allowing industry to focus on scouting the most promising developments in biotech. The panel will discuss what is unique to their individual searches and how they prioritize.

Moderator:
Bruce Booth – Partner, Atlas Venture

Panelists:
  • Irene Abrams – Senior Director, Technology and Innovation Development Office, Boston Children's Hospital
  • Michelle Browner – Senior Director, Partnership Management, Johnson & Johnson Innovation, Boston
  • Susan Kalled – Head, External Sciences, Discovery Biology and Translational Research, Shire
  • Rupert Vessey – Senior VP, Translational Development, Celgene
Share this:Email this pageShare this on LinkedInShare this on Twitter
Immuno-oncology: New advances + new targets + new partnerships = new cures?

Big pharma has a strong foothold in immuno-oncology, but with new biotechs coming up with novel platforms and technologies, the field is more exciting now than ever before. How are these new advances making immunotherapies more effective and bringing us closer to cures? This panel will address this question, provide an overview of the current partnership landscape, then discuss what makes new partners attractive and what differentiates new targets.

Moderator:
Michael G. King, Jr. – Managing Director, Senior Research Analyst, JMP Group

Panelists:
  • Iain Dukes – Senior VP, Business Development and Licensing, Merck
  • Ioannis Sapountzis – Global Head, Oncology Business Development and Licensing, Boehringer Ingelheim GmbH
  • Clifford J. Stocks – CEO, Theraclone Sciences, Inc.
Share this:Email this pageShare this on LinkedInShare this on Twitter
Instant biotech: Creating a clinical-stage startup by in-licensing assets

With numerous acquisitions and mergers among big pharma, and more programs from academics and biopharma than investors are willing to fund, many innovative, clinical-stage products that don't fit the mold are being left on the shelf. This leaves entrepreneurs in a perfect position to create startup companies with an instant pipeline. The panelists will discuss the multitude of options available when creating a biotech company by in-licensing assets, as well as their strategy on securing funding and the difficulties along the way.

Moderator:
Jeffrey L. Quillen – Partner, Foley Hoag LLP

Panelists:
  • Peter Kolchinsky – Managing Director and Portfolio Manager, RA Capital
  • Andrew Miller – VP, PureTech
  • Manos Perros – President and CEO, Entasis Therapeutics
  • Martin Tolar – President and CEO, Alzheon
Share this:Email this pageShare this on LinkedInShare this on Twitter
In the Spotlight
Digital health

Digital health is steadily growing and providing advances in the way health data is collected, organized and analyzed, which will influence patient treatment plans of the future. In years to come doctors may not only prescribe medicine, but also recommend a digital program for treatment. This panel will discuss how digital health has the potential to change the way therapeutics companies incorporate digital health into overall patient treatment strategies.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • John Brownstein – Chief Innovation Officer, Boston Children's Hospital
  • Thomas Klein – Founder and CEO, Cytolon
  • Eddie Martucci – VP, PureTech
Share this:Email this pageShare this on LinkedInShare this on Twitter
How does pharma get involved in an outside-the-box idea?

Every pharma company boasts about being innovation-driven, yet the majority of their R&D targets and approaches are in the same five therapeutic areas. Sit down with executives from pharma going after the white space areas to discuss why going into these overlooked areas alone can actually be wildly successful.

Moderator:
Chris Comeau – Partner, Ropes & Gray

Panelists:
  • Richard Andrews – President and CEO, Thrasos Therapeutics
  • Adam Keeney – VP and Global Head, External Innovation Operations, Sanofi
  • Benjamin Thorner – VP, Business Development and Licensing, North American Innovation Hubs, Merck
  • Craig D. Wegner – Head, Boston Emerging Innovations Unit, AstraZeneca
Share this:Email this pageShare this on LinkedInShare this on Twitter
Biomarkers and precision medicine

Advancements in biomarkers and precision medicine have the potential to radically change disease treatment and prevention. With greater understanding of individual patient information, more targeted and tailored treatment options are available. Panelists will discuss how the future of biomarkers and personalized medicine will impact R&D decisions and ultimately benefit patients.

Moderator:
Mike Ward – Global Director of Content, Informa Pharma Insights

Panelists:
  • Christine Grygon – Executive Director, Business Development and Licensing/Prescription Medicines, Boehringer Ingelheim GmbH
  • Ruth Phillips – Oncology Clinical Manager, IMS Health
  • Cecilia Schott – Head, Personalized Healthcare, Corporate Development and Ventures, AstraZeneca
Share this:Email this pageShare this on LinkedInShare this on Twitter
7:00–9:30 pm
Block Party Networking Reception
Technology Square

Technology Square
300/400 Technology Square Courtyard
Cambridge, MA

Step out into Cambridge's Technology Square for a Food Truck Block Party featuring some of Boston's most beloved food trucks. Sponsored by IMS Health, the Block Party reception joins biotech and culinary entrepreneurs together for an unforgettable evening of networking in Boston's biotech hub.

Sponsored by:
IMS HealthIMS Health

6:30–7:00 pm Shuttle buses will transport guests to the reception
8:45–9:30 pm Shuttle buses will transport guests to the conference hotel

Wednesday, September 16, 2015
7:30 am
Level 3, Atrium Lobby
7:30 am
Level 4, Grand Ballroom
Exhibition opens and Continental Breakfast
8:30–10:00 am
Pharma and Large Biotech Presentations
Moderation and Introduction by IMS Health Capital, Inc.


Share this:Email this pageShare this on LinkedInShare this on Twitter
Shire


Share this:Email this pageShare this on LinkedInShare this on Twitter
Boehringer Ingelheim


Share this:Email this pageShare this on LinkedInShare this on Twitter
Merck


Share this:Email this pageShare this on LinkedInShare this on Twitter
BioVentureHub


Share this:Email this pageShare this on LinkedInShare this on Twitter
Level 4, Exhibit Hall
8:00 am–6:00 pm
One-to-one Meetings ►
10:00 am–12:45 pm
Roundtable Discussions
Alternative partners roundtable

Clear methods are in place for how to approach pharma and even traditional investors but how do you get to the alternative partners that can make or break your startup? Venture philanthropists, patient groups, foundations and institutes discuss the best methods for getting the attention of all the other players.

Moderator:
Angus McQuilken – VP, Marketing and Communications, Massachusetts Life Sciences Center

Panelists:
  • Christopher de Souza – Director, Broadview Ventures
  • Sarah Frew – Director, Corporate Contracts and Alliances, Penn Center for Innovation, University of Pennsylvania
  • Gary M. Sclar – Associate Director, Dana-Farber Cancer Institute
  • Baiju Shah – CEO, BioMotiv
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma roundtable

Hear directly from your potential deal partners (large and small): What are they are looking for? Where do they source from? How do you get their attention? Execs from the leading pharma companies will share "dos and don'ts" and other helpful advice going into your afternoon pitches.

Moderator:
Ed Saltzman – President, Defined Health

Panelists:
  • Frank Borriello – VP, Head of Search and Evaluation, Global Business Development, Baxalta
  • Kara Bortone – Head, Company Sourcing, Johnson & Johnson Innovation, JLABS
  • Paola Casarosa – Corporate VP, Business Development and Licensing/Prescription Medicines, Boehringer Ingelheim GmbH
  • Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
Share this:Email this pageShare this on LinkedInShare this on Twitter
Investor roundtable

Investors from both corporate and financial venture firms will highlight innovative financing methods for early stage companies. We will cover topics that include:

  • VCs making seed-stage investments;
  • VC approaches to angel-backed companies; and
  • VCs doing mega-Series A rounds.

We'll emphasize the different approaches VCs take in investing in therapeutics, diagnostics, medical devices and the rapidly growing field of digital health. And we'll explore the flourishing collaboration between investors who have corporate backers (especially pharmaceutical companies) and those who are pure financial investors.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Marian Nakada – VP, Venture Investments, Johnson & Johnson Innovation, Boston
  • Marta New – Principal, Baxalta Ventures
  • Isai Peimer – Managing Director, MedImmune Ventures
  • Robert Weisskoff – Partner, Fidelity Biosciences
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:00 am–12:30 pm
Company Presentations ►
12:30–1:30 pm
Level 4, Exhibit Hall
Luncheon
1:30–4:00 pm
Afternoon pitches by startup companies

Pitch your startup to a panel of judges comprising BD execs, venture capitalists, and industry experts!

Qualifying startup companies are invited to pitch their company using no more than four slides, in four minutes. Our top-notch panel of judges will determine the winner by the quality and effectiveness of the pitch.

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Judges:
  • Jeffrey Arnold – Member, Mass Med Angels and Boston Harbor Angels
  • Thomas Luby – Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
  • Ivana Magovcevic-Liebisch – Senior VP and Head of Global Business Development, Teva Pharmaceuticals
  • Jason Rhodes – Partner, Atlas Venture
  • S. Edward Torres – Co-Founder and Managing Director, Lilly Ventures
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:30–5:00 pm
Company Presentations ►
4:00–5:45 pm
Level 4, Grand Ballroom
Exhibit Hall Meetup
4:30–5:00 pm
Johnson & Johnson Innovation presents Biotech Startup Day Prize

The grand prize for eligible entrepreneurs participating in the BioPharm America Biotech Startup Day will be awarded by Johnson & Johnson Innovation. The winner of this competition will have the opportunity to gain access to the use of a bench at one of Johnson & Johnson Innovation, JLABS managed locations for three months and six months of mentorship from a Johnson & Johnson Innovation team member. For specific eligibility requirements and application materials please visit the online information page.

The panel of judges will also choose a winner from among 20 pre-selected Startup Day applicants, and the winner will receive a presentation slot and complimentary full access registration to the 2016 BioPharm America event. For specific eligibility requirements and application materials please visit the online information page.

Share this:Email this pageShare this on LinkedInShare this on Twitter
5:45–7:00 pm
Level 4, Grand Ballroom
Exhibit Hall Reception
Thursday, September 17, 2015
7:30 am
Level 3, Atrium Lobby
7:30 am
Level 4, Grand Ballroom
Exhibition opens and Continental Breakfast
9:45 am–12:30 pm
Company Presentations ►
Level 4, Exhibit Hall
8:00 am–2:00 pm
One-to-one Meetings ►
9:15–10:15 am
Opening Panel Discussion
The evolution of the Regen Med ecosystem: What's required for its growth and sustainability?

The Boston-Cambridge area is rich with innovative biotech and regenerative medicine companies and is flush with cash from investors, but what's next? It takes more than hot technologies to build a viable business and more importantly, make an impact in patients' lives. What does the regenerative medicine and cell and gene therapy sector need to become sustainable long-term? Panelists will discuss the need for an integrated approach to building the necessary infrastructure for success and help define the critical roles of startups, established biopharma, clinicians, hospitals, manufacturers, and other stakeholders that can make or break this maturing industry.

Moderator:
Dolores Baksh – Innovation Leader, Cell Therapy Technologies, GE Healthcare

Panelists:
  • Chris Gemmiti – Business Development Lead, Wyss Institute for Biologically Inspired Engineering, Harvard University
  • Jeff Goater – Senior VP, Finance and Business Development, Voyager Therapeutics
  • Doug Kerr – Senior Director, Corporate Strategy and Portfolio Management, Biogen
  • Gary M. Sclar – Associate Director, Dana-Farber Cancer Institute
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30 am–12:45 pm
Panel Discussions
Gene and cell therapy

With breaking headlines on how gene therapy can transform the way we treat diseases, the sector is booming. This panel will discuss the latest industry advances, new partnerships, regulatory issues, and other exciting developments.

Moderator:
Brock Reeve – Executive Director, Harvard Stem Cell Institute

Panelists:
  • Frank Borriello – VP, Head of Search and Evaluation, Global Business Development, Baxalta
  • Robert Millman – CEO, Semma Therapeutics; Managing Director, MPM Capital
  • Stephen Potter – Chief Business Officer, AGTC
Share this:Email this pageShare this on LinkedInShare this on Twitter
Genome editing

We have seen exciting progress in the field of gene editing but how are these advances being applied to cell therapy and disease modification? How are techniques used in the lab like CRISPR, TALENS and ZFNs being translated to real benefits in patients, especially those with hereditary diseases? In addition to the scientific advances, what regulatory issues will need to be addressed before we can see treatments? What can we expect to see in the near and long-term?

Moderator:
Doug Kerr – Senior Director, Corporate Strategy and Portfolio Management, Biogen

Panelists:
  • Daniel G. Anderson – Associate Professor, Department of Chemical Engineering, Institute for Medical Engineering and Science, Harvard-MIT Division of Health Sciences and Technology, David H. Koch Institute for Integrative Cancer Research, MIT
  • Alexandra Glucksmann – Chief Operating Officer, Editas Medicine
  • Edward Lanphier – President and CEO, Sangamo BioSciences
  • Sven Ante (Bill) Lundberg – Chief Scientific Officer, CRISPR Therapeutics
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–1:30 pm
Level 4, Exhibit Hall
Luncheon
1:30–2:30 pm
Level 4, Exhibit Hall
Closing Reception
Arrow Up


© 2009–2015 EBD Group, Inc.